2015 Life Science Intermediates Market Consolidation: Who will not survive?

May 2015 | 35 pages | ID: 2DEBB47722BEN
Venture Planning Group

Abstracts

• Will the industry consolidate, decentralize, or undergo a bimodal transformation?
• How will the current trends affect the major market segments?
• Which companies will enter the market and which will not survive?

This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents:

• Internally developed and acquired technologies, and related capabilities.
• Proprietary technologies and patent litigations.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages

Contents

1. BASF

2. BAYER/LANXESS

3. CAMBREX

4. CLARIANT

5. DOWPHARMA

6. DSM

7. EVONIK

8. LONZA

9. NOVASEP

10. RHODIA

FOR EACH COMPANY, THE REPORT PRESENTS:

Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.